Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8DCC

SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 3 Bound to P2B-2F6 Fab

Summary for 8DCC
Entry DOI10.2210/pdb8dcc/pdb
DescriptorSpike protein S1, P2B-2F6 Fab light chain, P2B-2F6 Fab heavy chain, ... (5 entities in total)
Functional Keywordsimmunogen, antigen, design, vaccine, viral protein-immune system complex, viral protein/immune system
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains3
Total formula weight72193.37
Authors
Dickey, T.D.,Tolia, N.H. (deposition date: 2022-06-16, release date: 2022-07-06, Last modification date: 2024-10-23)
Primary citationDickey, T.H.,Tang, W.K.,Butler, B.,Ouahes, T.,Orr-Gonzalez, S.,Salinas, N.D.,Lambert, L.E.,Tolia, N.H.
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response.
Sci Adv, 8:eabq8276-eabq8276, 2022
Cited by
PubMed Abstract: The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the primary target of neutralizing antibodies and is a component of almost all current vaccines. Here, RBD immunogens were created with stabilizing amino acid changes that improve the neutralizing antibody response, as well as characteristics for production, storage, and distribution. A computational design and in vitro screening platform identified three improved immunogens, each with approximately nine amino acid changes relative to the native RBD sequence, and four key changes conserved between immunogens. The changes are adaptable to all vaccine platforms and compatible with mutations in emerging variants of concern. The immunogens elicit higher levels of neutralizing antibodies than native RBD, focus the immune response to structured neutralizing epitopes, and have increased production yields and thermostability. Incorporating these variant-independent amino acid changes in next-generation COVID vaccines may enhance the neutralizing antibody response and lead to longer duration and broader protection.
PubMed: 36103542
DOI: 10.1126/sciadv.abq8276
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

230083

數據於2025-01-15公開中

PDB statisticsPDBj update infoContact PDBjnumon